FR3085849B1 - Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire - Google Patents

Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire Download PDF

Info

Publication number
FR3085849B1
FR3085849B1 FR1858341A FR1858341A FR3085849B1 FR 3085849 B1 FR3085849 B1 FR 3085849B1 FR 1858341 A FR1858341 A FR 1858341A FR 1858341 A FR1858341 A FR 1858341A FR 3085849 B1 FR3085849 B1 FR 3085849B1
Authority
FR
France
Prior art keywords
pharmaceutical composition
topical use
inflammatory substance
mass
polyhydroxystearates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1858341A
Other languages
English (en)
Other versions
FR3085849A1 (fr
Inventor
Catherine Bulcourt
Alice Denis
Annie Segurani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Original Assignee
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA filed Critical Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority to FR1858341A priority Critical patent/FR3085849B1/fr
Priority to EP19787033.0A priority patent/EP3852726A1/fr
Priority to US17/276,693 priority patent/US20220023208A1/en
Priority to JP2021514330A priority patent/JP2022500446A/ja
Priority to CN201980060301.4A priority patent/CN112739326A/zh
Priority to PCT/FR2019/052116 priority patent/WO2020058603A1/fr
Publication of FR3085849A1 publication Critical patent/FR3085849A1/fr
Application granted granted Critical
Publication of FR3085849B1 publication Critical patent/FR3085849B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition pharmaceutique à usage topique se présentant sous la forme d'une émulsion de type eau dans huile comprenant pour 100% de sa masse : - de 60% à 80% massique d'une phase aqueuse gélifiée (A1) comprenant une substance inflammatoire, - de 20% à 40% massique d'une phase grasse (A2) comprenant au moins une huile et un système émulsionnant comprenant une combinaison d'au moins un agent tensioactif émulsionnant (Si) sélectionné parmi les éléments du groupe constitué par les compositions d'alkylpolyglycosides, les compositions d'alkylpolyglycosides et d'alcools gras, et d'au moins un agent tensioactif émulsionnant (S2) sélectionné parmi les éléments du groupe constitué par les esters de polyglycérols, les esters de polyglycérols alcoxylés, les polyhydroxystéarates de polyglycols, les polyhydroxystéarates de polyglycérols, les polyhydroxystéarates de polyglycérols alcoxylés.
FR1858341A 2018-09-17 2018-09-17 Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire Active FR3085849B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1858341A FR3085849B1 (fr) 2018-09-17 2018-09-17 Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire
EP19787033.0A EP3852726A1 (fr) 2018-09-17 2019-09-12 Composition pharmaceutique à usage topique comprenant au moins une substance anti-inflammatoire
US17/276,693 US20220023208A1 (en) 2018-09-17 2019-09-12 Pharmaceutical composition for topical use comprising at least one antiinflammatory substance
JP2021514330A JP2022500446A (ja) 2018-09-17 2019-09-12 少なくとも１つの抗炎症物質を含む局所使用のための医薬組成物
CN201980060301.4A CN112739326A (zh) 2018-09-17 2019-09-12 包含至少一种抗炎物质的用于局部使用的药物组合物
PCT/FR2019/052116 WO2020058603A1 (fr) 2018-09-17 2019-09-12 Composition pharmaceutique à usage topique comprenant au moins une substance anti-inflammatoire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1858341A FR3085849B1 (fr) 2018-09-17 2018-09-17 Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire

Publications (2)

Publication Number Publication Date
FR3085849A1 FR3085849A1 (fr) 2020-03-20
FR3085849B1 true FR3085849B1 (fr) 2021-01-01

Family

ID=65201466

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1858341A Active FR3085849B1 (fr) 2018-09-17 2018-09-17 Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire

Country Status (6)

Country Link
US (1) US20220023208A1 (fr)
EP (1) EP3852726A1 (fr)
JP (1) JP2022500446A (fr)
CN (1) CN112739326A (fr)
FR (1) FR3085849B1 (fr)
WO (1) WO2020058603A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3118578B1 (fr) * 2021-01-07 2024-03-08 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition pharmaceutique comprenant comme agent épaississant une composition qui présente des propriétés épaississantes de milieux polaires

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
FR2721607B1 (fr) 1994-06-28 1996-10-31 Seppic Sa Nouveaux dérivés d'ammoniums quaternaires, leur procédé de préparation et leur utilisation comme agents de surface.
JP2001181166A (ja) * 1999-12-22 2001-07-03 Lion Corp 油中水型乳化皮膚外用剤組成物
US20060241175A1 (en) * 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds
US7138394B2 (en) * 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
FR2852258B1 (fr) * 2003-03-14 2006-07-21 Emulsions notamment solaires de type eau-dans-huile, et leur procede de preparation
FR2852257B1 (fr) * 2003-03-14 2006-07-21 Emulsions eau-dans-huile, a forte teneur en phase aqueuse, obtenues par un procede simple et economique
ZA200507018B (en) * 2003-12-16 2008-02-27 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
FR2912651A1 (fr) 2007-02-21 2008-08-22 Oreal Emulsion e/h pour le soin de la peau.
WO2009039069A1 (fr) * 2007-09-20 2009-03-26 University Of Rochester Procédés et compositions pour le traitement ou la prévention d'états inflammatoires
GB0818473D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
FR2950060B1 (fr) * 2009-09-11 2011-10-28 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Nouveau polymere en poudre, procede pour sa preparation et utilisation comme epaississant
JP5769481B2 (ja) * 2011-04-15 2015-08-26 株式会社 資生堂 ウフェナマート含有皮膚外用剤
FR3004454B1 (fr) * 2013-04-12 2015-03-27 Seppic Sa Nouvelles emulsions eau-dans-huile a forte teneur en phase aqueuse, de consistances liquides et stables au stockage

Also Published As

Publication number Publication date
FR3085849A1 (fr) 2020-03-20
US20220023208A1 (en) 2022-01-27
CN112739326A (zh) 2021-04-30
JP2022500446A (ja) 2022-01-04
WO2020058603A1 (fr) 2020-03-26
EP3852726A1 (fr) 2021-07-28

Similar Documents

Publication Publication Date Title
EA200800258A1 (ru) Эмульсионные композиции пропофола для внутривенного введения, имеющие консервирующую эффективность
KR870002835A (ko) 이온화성 소수성약제의 약제학적 제조방법
WO2008129806A1 (fr) Composition d'émulsion de type huile-dans-eau
AR025040A1 (es) Auxiliar detergente acuoso multifase que contiene tensoactivos, procedimiento para su elaboracion y empleo del mismo y de aceites perfumados
DK1150969T3 (da) Alfa-azacyclomethylquinolinderivater til behandling af urininkontinens
FR3085849B1 (fr) Composition pharmaceutique a usage topique comprenant au moins une substance anti-inflammatoire
DK1651265T3 (da) Vaccineformuleringer der omfatter en olie-i-vand-emulsion
BR0207698A (pt) Adjuvante para uso em formulação de vacina, vacina, e, uso de um emulsificante polimérico
BR9907832A (pt) Composição de propofol contendo sulfito
EA200601460A1 (ru) Препарат микроэмульсии с высокой концентрацией пропофола для анестезирующих применений
NO20025629D0 (no) Formulering
JP2018168102A (ja) 水中油型乳化化粧料
BR0011782A (pt) Fluido de trabalho em metal, e, uso de uma emulsão água-em-óleo
WO2007059888A3 (fr) Emulsions speciales
DE602004014751D1 (de) Reinigungsmittel vom typ der multiplen emulsion
FR3042112B1 (fr) Produit de soin pour la peau epaissi
JP2005118776A5 (fr)
HUP0101302A2 (hu) Szilárd tisztálkodószer és hatásjavító forgácskompozíció
US7226901B2 (en) Stable transparent perfuming emulsion
FR3094636B1 (fr) Composition pharmaceutique à usage topique comprenant au moins une substance antifongique locale azolée
US10980717B2 (en) Aqueous perfume compositions
FR3085848B1 (fr) Composition pharmaceutique a usage topique comprenant au moins une substance anesthesiante locale
FR3086541B1 (fr) Composition cosmetique sous forme d'emulsion eau-dans-huile pour ameliorer le peignage de meches de cheveux
DE602005014175D1 (de) Feine Ö/W-Emulsion und ihre Verwendung im Kosmetikbereich
BR112015015847A2 (pt) composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200320

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7